FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from chief rival Eli Lilly. Novo expects to launch the higher, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that version to better compete with Lilly's obesity drug Z ...